1. Home
  2. AUBN vs TENX Comparison

AUBN vs TENX Comparison

Compare AUBN & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Auburn National Bancorporation Inc.

AUBN

Auburn National Bancorporation Inc.

HOLD

Current Price

$26.18

Market Cap

88.8M

Sector

Finance

ML Signal

HOLD

Logo Tenax Therapeutics Inc.

TENX

Tenax Therapeutics Inc.

HOLD

Current Price

$2.33

Market Cap

71.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AUBN
TENX
Founded
1907
1967
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
88.8M
71.1M
IPO Year
1996
2001

Fundamental Metrics

Financial Performance
Metric
AUBN
TENX
Price
$26.18
$2.33
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$29.67
AVG Volume (30 Days)
781.0
8.3M
Earning Date
04-28-2026
05-15-2026
Dividend Yield
4.61%
N/A
EPS Growth
13.66
N/A
EPS
1.29
N/A
Revenue
$619,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$20.26
N/A
Revenue Growth
0.81
N/A
52 Week Low
$21.60
$1.31
52 Week High
$28.88
$19.40

Technical Indicators

Market Signals
Indicator
AUBN
TENX
Relative Strength Index (RSI) 47.82 22.44
Support Level $25.09 $1.31
Resistance Level $27.00 $16.39
Average True Range (ATR) 0.22 0.32
MACD -0.01 -0.22
Stochastic Oscillator 28.92 6.57

Price Performance

Historical Comparison
AUBN
TENX

About AUBN Auburn National Bancorporation Inc.

Auburn National Bancorp Inc is a bank holding company registered with the Board of Governors of the Federal Reserve System (the Federal Reserve). As a bank holding company, the Company may diversify into a broader range of financial services and other business activities than are currently permitted to the Bank under applicable laws and regulations. The holding company structure also provides greater financial and operating flexibility than is presently permitted to the Bank. The Company's business is conducted through the Bank and its subsidiaries. Although it has no immediate plansto conduct any other business, the Company may engage directly or indirectly in several activities closely related to banking permitted by the Federal Reserve.

About TENX Tenax Therapeutics Inc.

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

Share on Social Networks: